SCHEMBL894700

SCHEMBL894700

Clc1ccc(CC2CCNCC2)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GBA1 P04062 1/20 0.66
ALDH1A1 P00352 1/20 0.51
KCNH2 Q12809 1/20 0.49
PRMT5 O14744 1/20 0.45
WDR77 Q9BQA1 1/20 0.45
HTR3A P46098 1/20 0.44
SLC6A4 P31645 4/20 0.43
FPR2 P25090 1/20 0.42
PROKR1 Q8TCW9 1/20 0.42
GMNN O75496 1/20 0.41
TP53 P04637 1/20 0.41
CYP3A4 P08684 1/20 0.41
ALOX15 P16050 1/20 0.41
TSHR P16473 1/20 0.41
NFKB1 P19838 1/20 0.41
THPO P40225 1/20 0.41
MTOR P42345 1/20 0.41
BLM P54132 1/20 0.41
GRIN1 Q05586 1/20 0.41
GRIN2B Q13224 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6968488 0.98 GBA1 (0.63) GBA1ALDH1A1KCNH2PRMT5WDR77
SCHEMBL4308696 0.89 GBA1 (0.52) GBA1ALDH1A1KCNH2HTR3ASLC6A4
SCHEMBL1119467 0.85 ALDH1A1 (0.59) GBA1ALDH1A1SLC6A4FPR2PROKR1
Trifluoroacetic Acid SCHEMBL3171388 0.84 GBA1 (0.53) GBA1ALDH1A1KCNH2
SCHEMBL11366707 0.83 GBA1 (0.50) GBA1KCNH2PRMT5WDR77HTR3A
SCHEMBL9562401 0.81 MAOB (0.53) GBA1PRMT5WDR77HTR3ASLC6A4
Oxalic Acid SCHEMBL1760844 0.80 GBA1 (0.47) GBA1ALDH1A1HTR3A
SCHEMBL25133603 0.80 GBA1 (0.66) GBA1PRMT5WDR77SLC6A4HRH4
SCHEMBL2948678 0.80 GBA1 (0.66) GBA1PRMT5WDR77SLC6A4GRIN1
SCHEMBL21799757 0.80 GBA1 (0.66) GBA1PRMT5WDR77SLC6A4HRH4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 146 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2006271-A9 SUBSTITUTED BICYCLIC CYCLIC DERIVATIVE AND USE THEREOF Asahi Kasei Pharma Corporation (JP) 2009-07-29 EP claimed
US-20090054401-A1 Substituted bicyclic derivatives and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2009-02-26 US claimed
EP-2006271-A2 SUBSTITUTED BICYCLIC CYCLIC DERIVATIVE AND USE THEREOF Asahi Kasei Pharma Corporation (JP) 2008-12-24 EP claimed
EP-0705825-A2 Diaminic compounds, preparation, use and intermediates Buckman Laboratoires International, Inc. (US) 1996-04-10 EP claimed
US-20260124309-A1 STAT6 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2026-05-07 US disclosed
US-12479816-B2 20-HETE formation inhibitors University of Pittsburgh—of the Commonwealth System of Higher Education (US) 2025-11-25 US disclosed
WO-2025049820-A1 STAT6 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2025-03-06 WO disclosed
EP-4506344-A1 1,4-DIHETEROCYCLIC SUBSTITUTED AROMATIC RING OR AROMATIC HETEROCYCLIC COMPOUND AND USE THEREOF Bebetter Med Inc. (CN) 2025-02-12 EP disclosed
US-20250034116-A1 1,4-DIHETEROCYCLIC SUBSTITUTED AROMATIC RING OR AROMATIC HETEROCYCLIC COMPOUND AND USE THEREOF BEBETTER MED INC. (CN) 2025-01-30 US disclosed
EP-3837263-B1 NEW HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS HOFFMANN LA ROCHE (CH) 2024-07-03 EP disclosed
CN-116615417-B 1, 4-Diheterocyclic group substituted aromatic ring or aromatic heterocyclic compound and application thereof 广州必贝特医药股份有限公司 2024-05-14 CN disclosed
US-20240150373-A1 HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2024-05-09 US disclosed
WO-1997023458-A1 SUBTYPE-SELECTIVE NMDA RECEPTOR LIGANDS AND THE USE THEREOF WARNER-LAMBERT COMPANY (US) 1997-07-03 WO disclosed
WO-1997023216-A1 4-SUBSTITUTED PIPERIDINE ANALOGS AND THEIR USE AS SUBTYPE SELECTIVE NMDA RECEPTOR ANTAGONISTS WARNER-LAMBERT COMPANY (US) 1997-07-03 WO disclosed
WO-1997023214-A1 4-SUBSTITUTED PIPERIDINE ANALOGS AND THEIR USE AS SUBTYPE SELECTIVE NMDA RECEPTOR ANTAGONISTS WARNER-LAMBERT COMPANY (US) 1997-07-03 WO disclosed
CN-1148853-A Alkylenediamine derivatives NIPPON CHEMIPHAR CO (JP) 1997-04-30 CN disclosed
US-5036077-A Antiseptics, preservatives, drugs, cosmetics, foods SANOFI (FR) 1991-07-30 US disclosed
US-4077958-A ANTIDEPRESSANTS E. R. SQUIBB & SONS, INC. (US) 1978-03-07 US disclosed
US-4007191-A ANTIDEPRESSANT E. R. SQUIBB & SONS, INC. (US) 1977-02-08 US disclosed
US-3935227-A ANTIDEPRESSANTS, ANTIANXIETY, ANTIINFLAMMATORY AGENTS E. R. SQUIBB & SONS, INC. (US) 1976-01-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054401-A1 Substituted bicyclic derivatives and use thereof LTB4R2, LTC4S, LTB4R GBA1 2652/4885ALDH1A1 1731/4885KCNH2 2052/4885
US-20260124309-A1 STAT6 DEGRADERS AND USES THEREOF STAT6, NCOR2, NCOR1 GBA1 4568/4885ALDH1A1 2085/4885KCNH2 4066/4885
US-20240150373-A1 HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS LIPC, LPL, MGLL GBA1 39/4885ALDH1A1 525/4885KCNH2 3236/4885
US-12479816-B2 20-HETE formation inhibitors CYP4A22, ALOX5, ALOX15 GBA1 2356/4885ALDH1A1 545/4885KCNH2 4440/4885
US-20250034116-A1 1,4-DIHETEROCYCLIC SUBSTITUTED AROMATIC RING OR AROMATIC HETEROCYCLIC COMPOUND AND USE THEREOF CYP46A1, CYP4A22, CYP2C19 GBA1 3355/4885ALDH1A1 233/4885KCNH2 1631/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.